Q4 2024 Earnings Call Transcript March 24, 2025 Lucid Diagnostics Inc. misses on earnings expectations. Reported EPS is ...

Lucid Diagnostics (LUCD) reports record test volumes and strategic milestones in Q4 2024. Learn how Medicare coverage & NCCN inclusion may fuel 2025 growth.

Reports Q4 revenue $1.197M vs $1.040M last year. “The Lucid team finished 2024 on a strong note and 2025-which promises to be a pivotal year-is ...

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -26.67% and 14.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PAVmed Inc.  ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business ...

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy "This update is an important ...

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, March 18 ...

Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...

LUCID DIAGNOSTICS ($LUCD) is expected to release its quarterly earnings data on Monday, March 24th before market open, per Finnhub. Analysts are expecting revenue of ...